Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14121396 | 0.84 | TTR (0.53) | HSD17B10TSHRHPGDALDH1A1KMT2A | |
| SCHEMBL17744335 | 0.80 | HSD17B10 (0.45) | HSD17B10TSHRHPGDALOX15ALDH1A1 | |
| SCHEMBL20639120 | 0.78 | CA3 (0.41) | ALOX15ALDH1A1SMN1; SMN2MAPK1KMT2A | |
| SCHEMBL900973 | 0.76 | KMT2A (0.37) | HSD17B10TSHRHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL900975 | 0.76 | GAA (0.44) | TSHRHPGDALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL8812557 | 0.76 | ALDH1A1 (0.46) | HSD17B10TSHRHPGDALOX15ALDH1A1 | |
| SCHEMBL14018146 | 0.76 | L3MBTL1 (0.39) | HSD17B10TSHRHPGDKMT2AMAPT | |
| SCHEMBL28323408 | 0.76 | KMT2A (0.37) | HSD17B10TSHRHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6441902 | 0.76 | MAPT (0.46) | HSD17B10TSHRHPGDALOX15ALDH1A1 | |
| SCHEMBL10672960 | 0.76 | MAPT (0.43) | HSD17B10TSHRALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20140315878-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315878-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | HSD17B10 2100/4885TSHR 3672/4885HPGD 2536/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | HSD17B10 4264/4885TSHR 4580/4885HPGD 3664/4885 |
| US-20150259327-A1 | Chemical Compounds | SULT2A1, SULT1A1, SULT1E1 | HSD17B10 2398/4885TSHR 831/4885HPGD 4483/4885 |
| US-20140315878-A1 | CHEMICAL COMPOUNDS | SULT2A1, SULT1A1, SULT1E1 | HSD17B10 2398/4885TSHR 831/4885HPGD 4483/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | HSD17B10 2940/4885TSHR 3645/4885HPGD 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.